Abstract: Disclosed herein are pharmaceutical compositions for the treatment of neurologic disorders comprising an effective amount of one or more mTOR inhibitors and/or one or more BDNF inducers and optionally an effective amount of one or more thyroid hormones. Further disclosed herein are methods of treating or preventing neurologic disorders comprising administering an effective amount of a pharmaceutical composition comprising one or more mTOR inhibitors and/or one or more BDNF inducers and optionally an effective amount of one or more thyroid hormones.

Abstract: Disclosed herein are pharmaceutical compositions to treat or prevent obesity, excess or overweight conditions, and metabolic syndrome comprising an effective amount of one or more mTOR inhibitors and optionally an effective amount of one or more thyroid hormones and/or an effective amount of one or more cholesterol-lowering agents. Further disclosed herein are methods of treating or preventing obesity, excess or overweight conditions, and metabolic syndrome comprising administering an effective amount of a pharmaceutical composition comprising one or more mTOR inhibitors and optionally an effective amount of one or more thyroid hormones and/or an effective amount of one or more cholesterol-lowering agents.

Abstract: Disclosed herein are pharmaceutical compositions to treat, prevent, reduce the incidence of, or reduce the severity of hepatic steatosis comprising an effective amount of one or more mTOR inhibitors and optionally an effective amount of one or more thyroid hormones. Further disclosed herein are methods of treating, preventing, reducing the incidence of, or reducing the severity of hepatic steatosis comprising administering an effective amount of a pharmaceutical composition of one or more mTOR inhibitors and optionally an effective amount of one or more thyroid hormones.

Abstract: Disclosed herein are pharmaceutical compositions for adjuvant and complementary therapies to treat, prevent, reduce the incidence of, or reduce the severity of cancer or one or more secondary or side effects of primary cancer treatments comprising an effective amount of one or more mTOR inhibitors and optionally an effective amount of one or more thyroid hormones. Further disclosed herein are methods of treating, preventing, reducing the incidence of, or reducing the severity of cancer and one or more secondary or side effects of primary cancer treatments comprising administering an effective amount of a pharmaceutical composition of one or more mTOR inhibitors and optionally an effective amount of one or more thyroid hormones.

Abstract: Disclosed herein are pharmaceutical compositions for the treatment of acquired brain injury (ABI), including traumatic brain injury (TBI) and acute non-traumatic brain injury (ANBI), post-traumatic stress disorder (PTSD), and other degenerative neurological disorders that may or may not be associated with ABI comprising an effective amount of one or more mTOR inhibitors and optionally an effective amount of one or more thyroid hormones. Further disclosed herein are methods of treating, preventing, reducing the intensity of or reducing the severity of ABI and/or PTSD, the method comprising administering an effective amount of one or more mTOR inhibitors and optionally an effective amount of one or more thyroid hormones.

Abstract: Disclosed herein are pharmaceutical compositions for the treatment of neurologic disorders comprising an effective amount of one or more mTOR inhibitors and/or one or more BDNF inducers and optionally an effective amount of one or more thyroid hormones. Further disclosed herein are methods of treating or preventing neurologic disorders comprising administering an effective amount of a pharmaceutical composition comprising one or more mTOR inhibitors and/or one or more BDNF inducers and optionally an effective amount of one or more thyroid hormones.

Abstract: Disclosed herein are pharmaceutical compositions to treat or prevent obesity, excess or overweight conditions, and metabolic syndrome comprising an effective amount of one or more mTOR inhibitors and optionally an effective amount of one or more thyroid hormones and/or an effective amount of one or more cholesterol-lowering agents. Further disclosed herein are methods of treating or preventing obesity, excess or overweight conditions, and metabolic syndrome comprising administering an effective amount of a pharmaceutical composition comprising one or more mTOR inhibitors and optionally an effective amount of one or more thyroid hormones and/or an effective amount of one or more cholesterol-lowering agents.

Abstract: Disclosed herein are pharmaceutical compositions for the treatment of cytokine storm syndrome, and methods of administering such compositions for the treatment of acute respiratory distress syndrome, and the prevention of multiple organ failure in patients with cytokine storm syndrome and/or acute respiratory distress syndrome, comprising an effective amount of one or more mTor inhibitors.

Abstract: Disclosed herein are pharmaceutical compositions to treat, prevent, reduce the incidence of, or reduce the severity of hepatic steatosis comprising an effective amount of one or more mTOR inhibitors and optionally an effective amount of one or more thyroid hormones. Further disclosed herein are methods of treating, preventing, reducing the incidence of, or reducing the severity of hepatic steatosis comprising administering an effective amount of a pharmaceutical composition of one or more mTOR inhibitors and optionally an effective amount of one or more thyroid hormones.

Abstract: Disclosed herein are pharmaceutical compositions for the treatment of cytokine storm syndrome, and methods of administering such compositions for the treatment of acute respiratory distress syndrome, and the prevention of multiple organ failure in patients with cytokine storm syndrome and/or acute respiratory distress syndrome, comprising an effective amount of one or more mTor inhibitors.

Abstract: Expandable laser catheters for utilizing laser energy to remove obstructions from body passages are described. In one embodiment, the laser catheter includes a shaftway having a distal end including a flexible portion configured in a series of radial folds. Multiple optical fibers, configured to transmit laser energy, extend along the shaftway and are attached to the flexible portion. An inflatable, ring-shaped balloon is attached to the catheter within the flexible portion. In use, the catheter is inserted into a body passage such as an artery, and advanced until the distal end is adjacent to an obstruction. The balloon is inflated to expand the flexible portion and to bring the optical fibers nearer the inner wall of the body passage. Laser energy is directed by the optical fibers toward targeted regions of the obstruction. As the catheter is advanced and the process repeated, a core is formed from the obstruction and contained within the flexible portion.

Abstract: An apparatus for expanding a chest cavity of a patient includes a tapered member and an expansion assembly coupled to the tapered member. The expansion assembly is configured to engage a sternum.

Abstract: A guide wire assembly includes a guide wire, an optical fiber, and an insulating coating. The guide wire has a distal end, a proximal end, and a bore extending through the wire between the distal and proximal ends. The an optical fiber also includes a distal end and a proximal end and is located within the bore of the guide wire. The optical fiber extends at least between the distal and proximal ends of the guide wire. The insulating coating is around an outside diameter of the guide wire, and is applied such that the distal ends of the guide wire and optical fiber are exposed.